WuXi PharmaTech Reports $500 Million in 2012 Revenues

WuXi PharmaTech reported another year of steadily increasing growth for 2012, something it seems to do with metronomic regularity. In 2012, the company’s net revenues rose 23% to just under $500 million and earnings (GAAP) climbed 7% to $86.6 million. WuXi’s mainstay business, China-based laboratory services, led the charge, rising almost 27% to $293 million. Manufacturing revenues increased 22.5% to $117 million, and US laboratory services were up 12% to $90 million. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: // //